Generic Pharma Share Price Target 2024 to 2030: Generic Pharma, involved in manufacturing and distributing both organic and inorganic chemicals, has expanded its operations to include buying and selling various pharmaceutical, medicinal, and medicated products. Originally established as Adi Rasayan Limited in 1992, the company is headquartered in Mumbai, Maharashtra. For several years, Generic Pharma’s stock has been categorized as a penny stock and has faced challenges in improving its market position. This article will provide predictions for Generic Pharma’s share price from 2025 onward, along with a financial analysis to aid investors in making informed decisions.
Generic Pharma Share Price Target
Generic Pharma Share Price Target 2024 ₹2.72, 2025 ₹4.29, 2026 ₹5.20, 2027 ₹5.20, 2028 ₹5.90, 2029 ₹6.33, To 2030 ₹7.23.
Generic Pharma Share Price Target 2024 To 2030 Forecast
| Year | Maximum Target (₹) | Minimum Target (₹) |
| 2024 | ₹5.45 | ₹2.72 |
| 2025 | ₹7.81 | ₹4.29 |
| 2026 | ₹9.52 | ₹4.39 |
| 2027 | ₹11.08 | ₹5.20 |
| 2028 | ₹13.47 | ₹5.90 |
| 2029 | ₹16.74 | ₹6.33 |
| 2030 | ₹20.22 | ₹7.23 |
Category: Stock Market
Latest News on Generic Pharma
Currently, Generic Pharma’s share price has shown no movement today but has increased over 45% on the Bombay Stock Exchange in the last 30 days.
See More:
Suzlon Share Price Target
RVNL Share Price Target
Mazagon Dock Share Price Target
Generic Pharma Share Price Target 2024, 2025, 2026, 2027, 2028, 2029 To 2030
Generic Pharma Share Price Target 2024 ₹2.72, 2025 ₹4.29, 2026 ₹5.20, 2027 ₹5.20, 2028 ₹5.90, 2029 ₹6.33, To 2030 ₹7.23.
Generic Pharma Share Price Target 2024
| Month | Maximum Target (₹) | Minimum Target (₹) |
| September | ₹4.59 | ₹2.23 |
| October | ₹4.85 | ₹2.39 |
| November | ₹5.10 | ₹2.57 |
| December | ₹5.45 | ₹2.72 |
See More: Glenmark Share Price Target
Generic Pharma Share Price Target 2025
| Month | Maximum Target (₹) | Minimum Target (₹) |
| January | ₹5.85 | ₹2.85 |
| February | ₹6.10 | ₹2.98 |
| March | ₹6.36 | ₹3.15 |
| April | ₹6.53 | ₹3.24 |
| May | ₹6.71 | ₹3.39 |
| June | ₹6.86 | ₹3.45 |
| July | ₹6.96 | ₹3.60 |
| August | ₹7.08 | ₹3.85 |
| September | ₹7.29 | ₹4.00 |
| October | ₹7.45 | ₹4.17 |
| November | ₹7.60 | ₹4.22 |
| December | ₹7.81 | ₹4.29 |
See More: IRFC Share Price Target
Generic Pharma Share Price Target 2026 to 2030
| Year | Maximum Target (₹) | Minimum Target (₹) |
| 2026 | ₹9.52 | ₹4.39 |
| 2027 | ₹11.08 | ₹5.20 |
| 2028 | ₹13.47 | ₹5.90 |
| 2029 | ₹16.74 | ₹6.33 |
| 2030 | ₹20.22 | ₹7.23 |
See More: ONGC Share Price Target
Financial Overview of Generic Pharma (2024)
| Financial Metric | Value (INR) | Year-on-Year Change |
| Revenue | ₹304.06 million | 19.16% |
| Operating Expense | ₹61.69 million | 229.93% |
| Net Income | ₹1.26 million | 111.18% |
| Net Profit Margin | 0.41% | 109.30% |
| EBITDA | ₹206.00 thousand | 92.32% |
| Total Assets | ₹711.26 million | 257.86% |
| Total Liabilities | ₹65.91 million | 45.01% |
| Total Equity | ₹645.35 million | |
Competitors of Generic Pharma
| Company | Market Capitalization (₹) |
| Generic Pharma | 192 crore |
| Sudarshan Chemical | 7,291 crore |
| Vidhi Spec | 2,245 crore |
| Kiri Industries | 1,899 crore |
| Bhageria Industries | 1,174 crore |
See More: Cochin Shipyard Share Price Target
Considerations Before Investing in Generic Pharma
Generic Pharma is expected to benefit from the Government of India’s Production-Linked Incentive (PLI) scheme, which aims to provide over ₹15,000 crores in incentives between 2021 and 2028. As India is dubbed the “Pharmacy of the World,” this can help boost small-cap companies. The future of the pharmaceutical industry in India relies heavily on small-cap companies, which typically exhibit high growth potential. With an expected CAGR of 10% for the pharmaceutical sector, Generic Pharma could see significant growth.
However, it is important to note that the company’s revenue and net income have not been consistently positive in recent years. In FY2022, Generic Pharma reported a significant decline in net income, with a further drop in 2023. The net income for FY2024 also showed a steep decline, indicating caution for potential investors.
